Fred Alger Management Inc. trimmed its holdings in Eli Lilly and Co (NYSE:LLY) by 6.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 53,436 shares of the company’s stock after selling 3,588 shares during the quarter. Fred Alger Management Inc.’s holdings in Eli Lilly and were worth $4,513,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of the stock. YorkBridge Wealth Partners LLC grew its holdings in Eli Lilly and by 0.8% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after buying an additional 24 shares in the last quarter. Pathstone Family Office LLC grew its holdings in Eli Lilly and by 100.0% in the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after buying an additional 29 shares in the last quarter. Princeton Portfolio Strategies Group LLC grew its holdings in Eli Lilly and by 0.3% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 17,860 shares of the company’s stock worth $1,470,000 after buying an additional 53 shares in the last quarter. Ironwood Investment Counsel LLC grew its holdings in Eli Lilly and by 1.4% in the 2nd quarter. Ironwood Investment Counsel LLC now owns 7,300 shares of the company’s stock worth $601,000 after buying an additional 100 shares in the last quarter. Finally, Clear Perspective Advisors LLC grew its holdings in Eli Lilly and by 2.2% in the 2nd quarter. Clear Perspective Advisors LLC now owns 4,940 shares of the company’s stock worth $407,000 after buying an additional 107 shares in the last quarter. 77.58% of the stock is owned by institutional investors and hedge funds.
In other news, insider Donald A. Zakrowski sold 876 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $77.55, for a total transaction of $67,933.80. Following the completion of the sale, the insider now owns 4,130 shares in the company, valued at approximately $320,281.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Donald A. Zakrowski sold 860 shares of the stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $76.50, for a total value of $65,790.00. The disclosure for this sale can be found here. Insiders have sold a total of 212,261 shares of company stock valued at $18,627,485 in the last quarter. Insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Co (NYSE LLY) opened at $79.61 on Monday. Eli Lilly and Co has a 52-week low of $73.69 and a 52-week high of $89.09. The company has a market capitalization of $87,220.55, a price-to-earnings ratio of 18.60, a PEG ratio of 1.48 and a beta of 0.28. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The company had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same quarter in the prior year, the firm earned $0.95 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. sell-side analysts forecast that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.